E-ISSN 0976-2833 | ISSN 0975-3583
 

Review Article 


The relation between CYP2C9 gene polymorphism and warfarin dosing in an Iranian population

Saeed Abtahi, Daryoush Rostami, Narges Ajilain, Thahmine Zafari, Reza Jafarzadeh Esfehani, Arash Poursheikhani, Mohammad Soudyab, Naseh Pahlavani, Ariane Sadr-Nabavi.

Abstract
Background: Warfarin is a common anticoagulant agent which is widely used in many countries. However, Warfarin is one of
those drugs which requires close monitoring and dosing while inappropriate could lead to hemorrhagic epoxides. Achieving
a desirable international normalized ratio (INR) range depends on various demographic factors and genetic factors are now
becoming an emerging area of interest in cardiovascular research. CYP2C9 is a gene encoding a member of cytochrome P450
enzyme which metabolizes many drugs. Genetic variation in this gene has been linked to abruption in Warfarin drug response. In
present study the effect of genetic polymorphisms in CYP2C9 gene and its response to Warfarin is investigated.
Methods: Total of 95 patients who had cardiovascular diseases and were using Warfarin for at least 3 months were enrolled in this
cross sectional study. Their DNA was extracted and the genetic polymorphisms in CYP2C9 gene (RS1799853 as CYP2C*2 and
RS1057910 as CYP2C9*3) were evaluated by using polymerase chain reaction and sequencing. Kruskal-Wallis test were used for
comparing the Warfarin values between the genotype groups. The SPSS software 22v was used for data analysis.
Results: Among the study population the prevalence of genotypes were as follow: CC/AA: 61.1, CT/AA: 17.9, CT/AC: 1.1, CC/AC:
3.6, TT/AA: 2.3, CC/CC: 0%. The CC/AA and CC/AC variants were related to Warfarin dose (P<0.05). These patients require lesser
doses of Warfarin in order to achieve the desired INR range.
Conclusion: Determination of genetic polymorphisms of effective genes in Warfarin response such as CYP2C9 gene is important
in initiating the Warfarin therapy and reducing possible complication of Warfarin. Considering genetic polymorphisms in every
population alongside with other effective factors on warfarin dosing should be considered in initiation of anticoagulant therapy.

Key words: Anticoagulants; Genotype; Polymorphism, Genetic; Warfarin


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Saeed Abtahi
Articles by Daryoush Rostami
Articles by Narges Ajilain
Articles by Thahmine Zafari
Articles by Reza Jafarzadeh Esfehani
Articles by Arash Poursheikhani
Articles by Mohammad Soudyab
Articles by Naseh Pahlavani
Articles by Ariane Sadr-Nabavi
on Google
on Google Scholar
Article Statistics
 Viewed: 1
Downloaded: 1


How to Cite this Article
Pubmed Style

Saeed Abtahi, Daryoush Rostami, Narges Ajilain, Thahmine Zafari, Reza Jafarzadeh Esfehani, Arash Poursheikhani, Mohammad Soudyab, Naseh Pahlavani, Ariane Sadr-Nabavi. The relation between CYP2C9 gene polymorphism and warfarin dosing in an Iranian population. . 2020; 11(1): 9-11. doi:10.5530/jcdr.2020.11.03


Web Style

Saeed Abtahi, Daryoush Rostami, Narges Ajilain, Thahmine Zafari, Reza Jafarzadeh Esfehani, Arash Poursheikhani, Mohammad Soudyab, Naseh Pahlavani, Ariane Sadr-Nabavi. The relation between CYP2C9 gene polymorphism and warfarin dosing in an Iranian population. http://www.jcdronline.org//?mno=93799 [Access: March 20, 2020]. doi:10.5530/jcdr.2020.11.03


AMA (American Medical Association) Style

Saeed Abtahi, Daryoush Rostami, Narges Ajilain, Thahmine Zafari, Reza Jafarzadeh Esfehani, Arash Poursheikhani, Mohammad Soudyab, Naseh Pahlavani, Ariane Sadr-Nabavi. The relation between CYP2C9 gene polymorphism and warfarin dosing in an Iranian population. . 2020; 11(1): 9-11. doi:10.5530/jcdr.2020.11.03



Vancouver/ICMJE Style

Saeed Abtahi, Daryoush Rostami, Narges Ajilain, Thahmine Zafari, Reza Jafarzadeh Esfehani, Arash Poursheikhani, Mohammad Soudyab, Naseh Pahlavani, Ariane Sadr-Nabavi. The relation between CYP2C9 gene polymorphism and warfarin dosing in an Iranian population. . (2020), [cited March 20, 2020]; 11(1): 9-11. doi:10.5530/jcdr.2020.11.03



Harvard Style

Saeed Abtahi, Daryoush Rostami, Narges Ajilain, Thahmine Zafari, Reza Jafarzadeh Esfehani, Arash Poursheikhani, Mohammad Soudyab, Naseh Pahlavani, Ariane Sadr-Nabavi (2020) The relation between CYP2C9 gene polymorphism and warfarin dosing in an Iranian population. , 11 (1), 9-11. doi:10.5530/jcdr.2020.11.03



Turabian Style

Saeed Abtahi, Daryoush Rostami, Narges Ajilain, Thahmine Zafari, Reza Jafarzadeh Esfehani, Arash Poursheikhani, Mohammad Soudyab, Naseh Pahlavani, Ariane Sadr-Nabavi. 2020. The relation between CYP2C9 gene polymorphism and warfarin dosing in an Iranian population. Journal of Cardiovascular Disease Research, 11 (1), 9-11. doi:10.5530/jcdr.2020.11.03



Chicago Style

Saeed Abtahi, Daryoush Rostami, Narges Ajilain, Thahmine Zafari, Reza Jafarzadeh Esfehani, Arash Poursheikhani, Mohammad Soudyab, Naseh Pahlavani, Ariane Sadr-Nabavi. "The relation between CYP2C9 gene polymorphism and warfarin dosing in an Iranian population." Journal of Cardiovascular Disease Research 11 (2020), 9-11. doi:10.5530/jcdr.2020.11.03



MLA (The Modern Language Association) Style

Saeed Abtahi, Daryoush Rostami, Narges Ajilain, Thahmine Zafari, Reza Jafarzadeh Esfehani, Arash Poursheikhani, Mohammad Soudyab, Naseh Pahlavani, Ariane Sadr-Nabavi. "The relation between CYP2C9 gene polymorphism and warfarin dosing in an Iranian population." Journal of Cardiovascular Disease Research 11.1 (2020), 9-11. Print. doi:10.5530/jcdr.2020.11.03



APA (American Psychological Association) Style

Saeed Abtahi, Daryoush Rostami, Narges Ajilain, Thahmine Zafari, Reza Jafarzadeh Esfehani, Arash Poursheikhani, Mohammad Soudyab, Naseh Pahlavani, Ariane Sadr-Nabavi (2020) The relation between CYP2C9 gene polymorphism and warfarin dosing in an Iranian population. Journal of Cardiovascular Disease Research, 11 (1), 9-11. doi:10.5530/jcdr.2020.11.03